Objective  To investigate the effects of butylphthalide combined with alteplase on neurological function, fibrinolytic activity and inflammation factors in patients with ischemic cerebral infarction.

  Methods  A total of 84 patients with ischemic cerebral infarction admitted to our hospital were randomly divided into two groups. The control group was treated with ateplase and the research group was treated with butylphthalide on the basis of the control group. The therapeutic effect, life ability, infarction size, National Institute of Health Stoke Scale(NIHSS) score, inflammatory factor level, renal function and incidence of adverse reactions were compared between the two groups.

  Results  The therapeutic effect of the study group was better than that of the control group (P < 0.05). After treatment, the living ability of the study group was higher, and the infarct size was less and NIHSS score was lower than the control group, the difference was statistically significant (P < 0.05). The inflammatory factor level of the study group was lower than that of the control group (P < 0.05). There was no significant difference in renal function between the two groups before treatment (P>0.05). After treatment, the creatinine clearance rate of the study group was higher than that of the control group, 24 h urine protein quantitation. The serum creatinine(Scr) level was lower than that of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

  Conclusion  For patientswith ischemic cerebral infarction, butylphthalide combined with alteplase is effective, which can effectively improve clinical symptoms, reduce inflammatory response, improve living ability, and reduce infarct size and NIHSS score. In addition, the treatments in combination can reduce the incidence of adverse reactions, and has higher safety, and can improve the prognosis of patients.